AZ
AstraZeneca
AZN · NYSE
$160.02 -1.65% (-$2.68)
1M +0.49%
Market Cap $248.0B
P/E Ratio 23.74x
Div. Yield 2.02%
ROE 21.75%
Bulios Fair Price
$162.08
1.3% upside
Current Price
$160.02
Undervalued Fair Value Overvalued
According to Bulios Fair Price, AZN is currently trading close to its fair value. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
8/9Valuation
53 /100
Fair P/E 23.74x
EV/EBITDA 13.32x
PEG 0.53x
Growth
82 /100
Growing EPS growth 45.80%
Rev. growth 9.82%
Book val. growth 9.53%
Profitability
92 /100
Strong Gross margin 81.88%
Net margin 17.02%
FCF margin 14.24%
Quality
76 /100
Excellent ROIC 12.83%
ROE 21.75%
Asset turnover 0.53x
Debt
69 /100
Low Debt/Equity 0.64x
Current ratio 0.89x
Net debt/EBITDA 1.32x
Stability
46 /100
Moderate Beta 0.21x
Rev. volatility 7.46%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about AZN
Online
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Pascal Claude Roland Soriot
Employees
96,100
Headquarters
Cambridge
Upcoming events
30 OCT
Earnings
Upcoming earnings report